Why prices are falling
Three forces converged: resolved shortages restored brand supply, compounded competition proved there was demand at lower price points, and direct-to-patient channels (NovoCare and partners) let manufacturers sell cash-pay without insurer markups. The result is the most affordable branded semaglutide pricing to date, aimed squarely at self-pay patients.
Self-pay price snapshot
| Option | Approx. self-pay price | Notes |
|---|---|---|
| Injectable Wegovy (maintenance) | ~$349/mo | Cash-pay via direct channels |
| Injectable Wegovy (intro, starter doses) | ~$199/mo first 2 months | Limited-time offer |
| Oral Wegovy pill (start) | ~$149/mo | ~$5/day starting-dose offer |
| Compounded semaglutide | Varies by provider | Not FDA-approved; verify pathway |
The self-pay trend
Effect on the compounded market
Lower brand pricing narrows the historic cost advantage of compounded semaglutide. When compounded vials cost a small fraction of brand pens, price drove the market; as approved products approach a few hundred dollars monthly, the gap shrinks and the compounded value proposition weakens, especially given the regulatory and quality questions covered elsewhere in our journal.
What to watch for
Cash-pay offers change frequently and often carry conditions: specific doses, first-month-only pricing, pharmacy restrictions, or auto-refill requirements. Read the terms, confirm the ongoing (not just intro) price, and check whether your insurance would actually beat the cash price. Teaser pricing that jumps at maintenance is exactly the pattern to scrutinize.
Bottom line
Semaglutide is more affordable through official channels than at any point since launch, which changes the math for anyone who chose compounded routes purely on cost. Price all of your options — injectable brand, oral brand, and any compounded route — for your specific dose and coverage, and confirm the sustained monthly figure before committing. See our compounded vs Wegovy cost guide.
Cash price vs insurance
A lower cash price is not automatically your best price. For patients with obesity or diabetes coverage, an insurance copay may still beat the self-pay figure, while others without coverage now have a viable direct-pay path for the first time. The calculus also depends on dose: introductory offers often apply only to starter doses, and the monthly cost at a maintenance dose is the number that actually matters over a year of treatment. Before switching programs on price alone, confirm three things: the sustained maintenance price rather than an intro rate, whether the offer requires auto-refill or a specific pharmacy, and whether your own plan would cover the medication more cheaply. Only then can you compare the true annual cost of injectable brand, oral brand, and any compounded route on equal footing.
Frequently asked questions
How much does Wegovy cost self-pay now?
Around $349/month for injectable maintenance via direct cash-pay channels, with a limited intro offer near $199/month for the first two months on starter doses. The oral pill starts near $149/month.
Why did Novo Nordisk cut prices?
Resolved shortages restored supply, compounded competition showed demand at lower prices, and direct-to-patient channels let the manufacturer sell cash-pay at lower markups.
Is compounded semaglutide still cheaper?
Sometimes, but the gap has narrowed as brand self-pay pricing fell. Compounded semaglutide is not FDA-approved, which is a separate consideration from price.
Do these prices change?
Yes. Cash-pay offers change frequently and carry conditions. Always confirm the ongoing maintenance price, not just an introductory rate.
References
- ABC News. FDA approves Wegovy pill; Novo Nordisk price changes. 2025-2026.
- Novo Nordisk. Wegovy pill availability and self-pay pricing. January 2026.
- Applied Clinical Trials. Wegovy pill self-pay pricing. 2026.